Q2 FY2026 · ended Jun 30, 2026 · Revenue $730,571, +106.7% YoY · Filed Aug 14, 2026
20/20 Biolabs, Inc. (AIDX) files with the SEC under industry code 8734, Services-Testing Laboratories. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $730,571 and a net loss of $1.5 million. As of Jun 30, 2026 it held $4.5 million in cash and investments and $572,448 in total debt.
Revenue
$730,571
+106.7% vs prior quarter
Net income
$-1.51M
+30.7% vs prior quarter
Operating cash flow
$-605,460
+53.0% vs prior quarter
Free cash flow
—
EPS
$-0.26
+7.1% vs prior quarter
Dividend per share
None
Shares outstanding
12.77M
+20.3% vs prior quarter
Net cash
$3.97M
Q2 FY2026
Operating margin
-170.3%
Q2 FY2026
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- AIDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1139685
- Former names
- 20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- Neogenomics Inc NEO
- Hypha Labs, Inc. FUNI
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|
| Revenue | $730,571 | $353,375 |
| Operating income | -$1.2M | -$1.4M |
| Net income | -$1.5M | -$2.2M |
| Diluted EPS | -$0.26 | -$0.28 |
| Operating cash flow | -$605,460 | -$1.3M |
| Total assets | $6.1M | $5.8M |
| Total liabilities | $3.0M | $3.0M |
| Stockholders' equity | $1.6M | $2.6M |
| Cash and investments | $4.5M | $4.2M |
| Total debt | $572,448 | $618,771 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 10, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 19, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 167 20/20 Biolabs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.